Alliance for Regenerative Medicine - Disease SpotlightDisease Facts:Description:+ Strokes disrupt the Strokeflow of blood to the + Leading Cause of Disability in the USbrain, damaging braintissue Stroke, caused by a disruption in is estimated that less than 5% of patients will be treated with its the flow of blood to the brain, is stroke victims are able to receive proprietary stem cell product 13- the third most deadly disease in emergency treatment. 19 days post-stroke, thus dramati-Patients: the US and the leading cause of cally widening the treatment Even with emergency+ 795,000 Americans serious disability. Someone in the window for ischemic stroke. The treatments, stroke often leavessuffer strokes each year US has a stroke every 40 seconds, aim of the therapy is to repair and survivors with severe disabilities + Stroke is the third and every three to four minutes, regenerate the brain after an including loss of mobility, pain, someone dies of stroke. When a ischemic stroke and thus reduceleading cause of death numbness, memory loss, stroke occurs, brain cells begin to patient disability and overall costsin the US difficulty talking, and impaired die in a matter of minutes from for caring for these patients. cognitive ability. Stroke victims oxygen deprivation, and over Animal studies have shown that may also lose the ability to careCause: time damage caused by inflam- Aldagen’s therapy improves for themselves and require a mation and other mechanisms blood flow to the brain and+ Blood clots or plaque constant caretaker or hospice leaves many patients with motor function, and reverses thebuild-up in the arteries, care, which can be emotionally permanent physical or cognitive decline in cell viability. Athersys,disrupting the supply of and financially draining for disability. The two most common headquartered in Cleveland, Ohio families. Physical therapy,blood to the brain types of stroke are ischemic and is also undergoing a Phase I trial extended hospitalization and hemorrhagic. Ischemic strokes for its product MultiStem®, to long term institutional care account for 87% of the 795,000 treat ischemic stroke. Multi-Cost of care: required for many victims of strokes that occur in the US every Stem®, is an “off the shelf” cell+ $73.7 billion in 2010 for stroke represent an enormous year and are caused when a therapy that has been shown in economic and social burden – thestroke-related medical blood clot or other mass in the preclinical models of stroke and American Heart Association arteries severely reduces blood other forms of neurological dam- recently estimated that theRM and Stroke: flow to the brain. The onset of age to repair damaged tissue annual aggregate costs of stroke stroke is generally sudden and throughout the body through+ 8 companies sponsoring exceed $73 billion. without warning. Unfortunately, multiple mechanisms of action,10 enrolling, ongoing, or the only non-surgical emergency The lack of treatment options for resulting in significant functionalcompleted clinical trials treatment available for ischemic stroke represents an enormous recovery. The company plans tostudying the use of stroke must be administered gap in medical care given its high initiate a Phase II trial in strokeautologous or allogeneic within 3 to 4 hours, and is only incidence and severity. However, patients in 2011. Celgene expected to help victims recover regenerative medicine technolo- Corporation will also soonmesenchymal bone more fully, not reverse the gies are bringing new hope for conduct a Phase II trial usingmarrow cells, neural stem repairing the debilitating effects placenta-derived stem cells. effects of the stroke. Due to thecells, and human-placenta narrow window of intervention, it of stroke through the use of The high incidence of strokederived cells to restore living cells and tissues. Several globally represents a cleardamaged brain tissue Alliance members have promising opportunity for U.S. companies clinical programs in ischemic to establish technology stroke. Aldagen, based in North leadership to address this global Carolina, is developing a health issue. Regenerative regenerative medicine therapy medicine therapies currently consisting of autologous (self- The Alliance for being developed in the US may donated) stem cells capable of Regenerative Medicine be the best hope for the millions improving blood flow to ischemic of stroke victims across the world (ARM) was formed to tissues. The Company is currently faced with a lifetime of disability advance regenerative enrolling patients in a Phase II and impairment.medicine by representing trial in which ischemic stroke and supporting the community of + Regenerative Medicine—In Brief companies, academic What is regenerative medicine? tissue and renew biologic products addressing many more research institutions, Regenerative medicine (RM) is a function in the body is what conditions advancing in clinicalpatient advocacy groups, rapidly evolving interdisciplinary distinguishes RM from other trials. RM holds the promise of foundations, and other field in health care that trans- types of treatments and brings treating a broad range of dis-organizations before the lates fundamental knowledge in new hope for dramatically eases that collectively represent Congress, federal biology, chemistry and physics improving clinical outcomes and a substantial burden to ouragencies and the general into materials, devices, systems curing disease. healthcare system, including public. and therapeutic strategies, What diseases can RM treat? acute and chronic conditions including cell-based therapies, such as diabetes, congestive RM products are currently on For more information, which augment, repair, replace the market for the treatment of heart failure, Parkinson’s please visit us online at: or regenerate organs and wounds, cartilage defects, and disease, stroke, renal disease, tissues. The ability to repair diabetic foot ulcers, with spinal cord injury, and ALS.